bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.09.10.612042

Characterisation of cell cycle checkpoint kinases in Toxoplasma gondii

Abstract

Toxoplasma gondii is a protozoan parasite in the apicomplexan phylum. Apicomplexan parasites replicate using a variety of non-canonical cell division modes, distinct from binary fission, whose molecular regulation is incompletely understood. T. gondii replicates by endodyogeny in its intermediate hosts, and by endopolygeny in its definitive host. To improve our understanding of how these unusual, flexible cell division modes are regulated, we characterised the T. gondii homologues of the cell-cycle checkpoint kinases ATM and ATR. These phosphoinositol-3-kinase-like kinases are entirely absent in some related parasites including Plasmodium; in T. gondii they are present but their putative checkpoint roles were previously uncharacterised. Both TgATM and TgATR were found to be dispersed throughout the parasite, rather than restricted to the nucleus, and they did not detectably relocate to the nucleus after DNA damage. Nevertheless, they were both required for checkpoint responses to DNA damage, including acute replication slowing and phosphorylation of the DNA damage marker histone H2AX. Unusually, the two kinases seemed to cooperate in the checkpoint response, with the loss of either one largely ablating the response, regardless of the type of DNA damage. Thus, T. gondii clearly retains a DNA-damage-responsive checkpoint, but some of its key features differ from the well-studied checkpoint in human cells. AUTHOR SUMMARYToxoplasma is one of the most widespread parasites of humans, with a large proportion of the global population being infected. Infection usually causes no symptoms, but can have severe consequences in pregnant women and immunocompromised people. The Toxoplasma parasite is a single-celled organism, related to other parasites that cause important human diseases like malaria. All these parasites are distinctive in having unusual modes of replication: unlike human cells, they do not replicate by simply splitting in two. Furthermore, drugs to treat toxoplasmosis usually act to suppress the parasites replication. Therefore, it is important to understand how this unusual replication is controlled, both for our fundamental understanding of cell division modes, and to ensure effective drug treatment of toxoplasmosis. Here, we characterised for the first time the proteins that control the Toxoplasma cell cycle by responding to DNA damage. We report that a damage-responsive checkpoint exists, but has some unusual features.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Johnson, M. K., Chelaghma, S., Koreny, L., Waller, R. F., Merrick, C. J.. 2024-09-10. Characterisation of cell cycle checkpoint kinases in Toxoplasma gondii. https://doi.org/10.1101/2024.09.10.612042

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

pTRIP, a novel integration plasmid for Listeria monocytogenes

In the past decades, several tools to genetically modify the human pathogen Listeria monocytogenes were developed. Here, we constructed a new integrative plasmid system for L. monocytogenes named pTRIP, for treB insertion plasmid. pTRIP is a vector which stably integrates into the treB locus of the wild type EGD-e. This locus encodes the sole trehalose-specific EIIB and EIIC component of a phosphotransferase system. Successful integration leads to the disruption of treB and thus, to an inability of the resulting L. monocytogenes strains to grow on trehalose as sole carbon source. Due to integration through double homologous recombination, it is the first integrative system which does not require antibiotic selection pressure. To assess functionality of the pTRIP system, prfA and its native promoter region were integrated into the treB locus of a {Delta}prfA strain. Complementation was confirmed in 78% of the isolated clones, indicating successful integration of prfA into the treB locus. We further constructed derivatives of pTRIP harboring the constitutive Pp60 (pTRIP1) and the inducible Prha (pTRIP2) promoter to further expand application possibilities. Microscopic analyses confirmed the functionality of both promoter constructs and showed dose-dependent induction for Prha. pTRIP is an efficient tool for stable gene expression as well as functional studies and expands genetic modification possibilities for L. monocytogenes.

microbiology↗

A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.

microbiology↗

Host soluble inositol phosphate signaling promotes coronavirus replication

Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.

microbiology↗